FCM
ABUS icon

FourWorld Capital Management’s Arbutus Biopharma ABUS Stock Holding History

FourWorld Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,570,000
Closed -$4.85M – 28
2024
Q2 		$4.85M Hold
1,570,000
– – 2.91% 8
2024
Q1 		$4.05M Buy
+1,570,000
New +$4.07M 2.58% 12

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

FourWorld Capital Management's ABUS Position: Q4 2025 in Review

FourWorld Capital Management sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 1,020,910 shares — an estimated $4.63M sold.

FourWorld Capital Management first reported a position in ABUS in Q1 2022 and held it in 15 quarters. The position peaked at $11.4M in Q3 2024. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • FourWorld Capital Management reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
  • FourWorld Capital Management sold 1,020,910 Arbutus Biopharma shares in Q4 2025, an estimated $4.63M.
  • FourWorld Capital Management first reported a position in Arbutus Biopharma in Q1 2022 and held it in 15 quarters.
  • FourWorld Capital Management's Arbutus Biopharma position peaked at $11.4M in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on FourWorld Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.